Cargando…

Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia

Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catellani, Silvia, Pierri, Ivana, Gobbi, Marco, Poggi, Alessandro, Zocchi, Maria Raffaella
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078937/ https://www.ncbi.nlm.nih.gov/pubmed/21533122 http://dx.doi.org/10.1371/journal.pone.0018925

Ejemplares similares

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment
por: Poggi, Alessandro, et al.
Publicado: (2012)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Expansion of vdelta1 T lymphocytes reactive to c. albicans IN HIV-1 infected patients: effect of influenza virus vaccine
por: Zocchi, Maria Raffaella, et al.
Publicado: (2010)

Leukemic retinophaty, the first manifestation in a case of acute myelogenous leukemia
por: Scripcă, Oana Roxana, et al.
Publicado: (2018)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by (1)H NMR spectroscopy
por: Dewar, Brian J., et al.
Publicado: (2010)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Chronic Myelogenous Leukemia Cells Contribute to the Stromal Myofibroblasts in Leukemic NOD/SCID Mouse In Vivo
por: Shirasaki, Ryosuke, et al.
Publicado: (2012)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
por: Kim, Soo Jung, et al.
Publicado: (2014)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8(+) T-cell large granular lymphocytic leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
por: Jelinek, Jaroslav, et al.
Publicado: (2011)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia
por: Wang, Xiao, et al.
Publicado: (2023)

Gingival Leukemic Infiltration in Chronic Lymphocytic Leukemia
por: Kacem, Karima, et al.
Publicado: (2019)

Hereditary asplenic-athymic mice: transplantation of human myelogenous leukemic cells
Publicado: (1976)

Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells
Publicado: (1982)

γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy
por: Poggi, Alessandro, et al.
Publicado: (2014)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients
por: Delord, Marc, et al.
Publicado: (2013)

Caffeic Acid Enhances the Anti-Leukemic Effect of Imatinib on Chronic Myeloid Leukemia Cells and Triggers Apoptosis in Cells Sensitive and Resistant to Imatinib
por: Feriotto, Giordana, et al.
Publicado: (2021)

Ontogeny of Ia and IgD on IgM-bearing B lymphocytes in mice
Publicado: (1977)

Defective Expression and Function of the Leukocyte Associated Ig-like Receptor 1 in B Lymphocytes from Systemic Lupus Erythematosus Patients
por: Colombo, Barbara M., et al.
Publicado: (2012)

Antigen Presenting Cells and Stromal Cells Trigger Human Natural Killer Lymphocytes to Autoreactivity: Evidence for the Involvement of Natural Cytotoxicity Receptors (NCR) and NKG2D
por: Poggi, Alessandro, et al.
Publicado: (2006)

Secretion of Transforming Growth Factor‐ß by Human Myelogenous Leukemic Cells and Its Possible Role in Proliferation of the Leukemic Cells
por: Komatsu, Keiko, et al.
Publicado: (1989)

High CXCR3 on Leukemic Cells Distinguishes IgHV(mut) from IgHV(unmut) in Chronic Lymphocytic Leukemia: Evidence from CD5(high) and CD5(low) Clones
por: Manukyan, Gayane, et al.
Publicado: (2020)

Correction: Defective Expression and Function of the Leukocyte Associated Ig-like Receptor 1 in B Lymphocytes from Systemic Lupus Erythematosus Patients
por: Colombo, Barbara M., et al.
Publicado: (2012)

Calcitonin receptor gene expression in K562 chronic myelogenous leukemic cells
por: Mould, Richard, et al.
Publicado: (2003)

A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib
por: Park, Mi-Jung, et al.
Publicado: (2014)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
por: Tracy, Alexis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_icffkp7sc4k4r6grd8anb95bra